Review of extralabel use of isoxazolines for treatment of demodicosis in dogs and cats

Xueying Zhou 1Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA 50011.

Search for other papers by Xueying Zhou in
Current site
Google Scholar
PubMed
Close
 DVM
,
Alexandra Hohman 2Department of Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA 50011.

Search for other papers by Alexandra Hohman in
Current site
Google Scholar
PubMed
Close
 DVM
, and
Walter H. Hsu 2Department of Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA 50011.

Search for other papers by Walter H. Hsu in
Current site
Google Scholar
PubMed
Close
 DVM, PhD

Click on author name to view affiliation information

Abstract

Amitraz is presently the only FDA-approved treatment for demodicosis in dogs in the United States. Amitraz treatment involves a protracted course of administration and risks of severe adverse effects such as sedation, bradycardia, and respiratory depression, which are caused by activation of α2-adrenergic receptors. Other treatment options include macrocyclic lactones and lime sulfur, but these products have varied efficacy and high risks of adverse effects. Several recent studies have indicated that isoxazolines are capable of reducing Demodex mite counts in canine and feline patients with demodicosis by ≥ 99% in as little as 1 month with few adverse effects. This article reviews the status of isoxazolines in regard to labeled uses in dogs and cats in the United States, extralabel clinical use for treatment of demodicosis in these species, and safety of orally administered formulations of these drugs.

Abstract

Amitraz is presently the only FDA-approved treatment for demodicosis in dogs in the United States. Amitraz treatment involves a protracted course of administration and risks of severe adverse effects such as sedation, bradycardia, and respiratory depression, which are caused by activation of α2-adrenergic receptors. Other treatment options include macrocyclic lactones and lime sulfur, but these products have varied efficacy and high risks of adverse effects. Several recent studies have indicated that isoxazolines are capable of reducing Demodex mite counts in canine and feline patients with demodicosis by ≥ 99% in as little as 1 month with few adverse effects. This article reviews the status of isoxazolines in regard to labeled uses in dogs and cats in the United States, extralabel clinical use for treatment of demodicosis in these species, and safety of orally administered formulations of these drugs.

All Time Past Year Past 30 Days
Abstract Views 929 0 0
Full Text Views 1697 1226 115
PDF Downloads 1192 660 61
Advertisement